导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 1.77% | 1821/4773 |
| 近一周 | -2.56% | 2547/5462 |
| 近一月 | -5.15% | 3080/5421 |
| 近一季 | -9.52% | 3241/5209 |
| 近半年 | -7.32% | 3202/4920 |
| 近一年 | 6.37% | 1470/4366 |
| 近两年 | 68.47% | 1007/2954 |
| 近三年 | 33.51% | 917/2253 |
| 成立以来 | 110.82% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
1.91% 1137/4961 |
18.25% 1402/5312 |
- - |
- - |
| 2025 | 29.84% 1374/4813 |
1.93% 1511/3635 |
1.72% 2199/4076 |
24.22% 1488/4524 |
0.80% 1760/4813 |
| 2024 | 6.35% 1767/3463 |
-2.83% 1443/2808 |
-5.32% 1690/3014 |
15.50% 1700/3129 |
0.09% 1270/3463 |
| 2023 | -6.64% 866/2656 |
7.54% 559/2280 |
-4.26% 1109/2385 |
-4.81% 1230/2515 |
-4.73% 1154/2655 |
| 2022 | -18.54% 722/2207 |
-13.59% 793/1919 |
2.84% 1251/2016 |
-10.53% 422/2113 |
2.47% 926/2208 |
| 2021 | 14.36% 337/1822 |
-2.08% 578/1255 |
8.80% 605/1330 |
4.31% 369/1466 |
2.92% 497/1822 |
| 2020 | 19.50% 734/1250 |
-4.22% 346/1028 |
15.69% 479/1067 |
5.40% 921/1164 |
2.32% 999/1184 |
| 2019 | 24.32% 621/1092 |
30.55% 243/754 |
-9.85% 696/804 |
-0.01% 571/850 |
5.64% 696/918 |
| 2018 | -31.80% 506/834 |
- - |
- - |
- - |
-12.20% 421/691 |
| 2017 | -1.10% 491/714 |
- - |
- - |
- - |
- - |
| 2016 | -17.01% 393/605 |
- - |
- - |
- - |
- - |
| 2015 | 37.00% 51/575 |
- - |
- - |
- - |
- - |
| 2014 | 35.52% 144/237 |
- - |
- - |
- - |
- - |
| 2013 | 15.74% 25/186 |
- - |
- - |
- - |
- - |
| 2012 | -9.92% 140/140 |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 港股医疗ETF | 1.4546 | 31.90% |
| 华富中证港股通创新药指数型发起式A | 1.1637 | 30.96% |
| 天弘恒生沪深港创新药精选50ETF发起联接A | 1.3128 | 30.52% |
| 中欧中证港股通创新药指数发起A | 1.6103 | 30.52% |
| 嘉实中证港股通创新药指数发起式C | 0.8566 | 30.50% |
| 中欧中证港股通创新药指数发起C | 1.4583 | 30.44% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8927 | 30.26% |
| 景顺长城中证港股通创新药ETF联接C | 1.4696 | 29.97% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8736 | 29.94% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8719 | 29.88% |
| 农银中证500指数 VS. 长安沪深300非周期A(740101) |